Buy-side orders:
All of these orders expire on August 17th if not filled.
Incyte (INCY): Genomic company is poised as the market leader in its field. Looks like they have managed to successfully outspend their competition, and they've managed to differentiate themselves from Celera, a fine accomplishment.
Technically, the stock has nearly hit a double bottom. I expect a partial retrace, and then a journey up to test resistance at 25 bucks a share. We'll see what happens then.
Ascential Software (ASCL), formerly known as Informix:
Same excuse as I posted on message #49 of this thread. Message 16057539 - one problem is that my price target is a little low. Management seems to be keeping the stock price up with their intense buyback program. Good for them, I hope the stock crashes just a bit further to nail this order.
Synopsys (SNPS):
These guys just might have enough firepower to make it back on the Nasdaq 100 next year. They went through a complete overhaul of their licensing systems, but as semiconductor companies begin to contract, when they retool, they will also be overhauling their software. That's where the big players of SNPS, CDN and AVNT come into play. SNPS and CDN are both on the Midcap 400. SNPS is more expensive in terms of P/E, but their balance sheet is so much stronger and their management is sharper than CDN's. Unfortunately, a little too late here technically, but I'll play for a pullback on the recent rally.
Sepracor (SEPR):
Biotech firm. Very risky. Losing lots of money when they pour it into R&D, and hopes for big returns loom near. Stock is technically on a nice uptrend, although it is very subtle. The play here is purely on a 'greater fool theory' basis.. maximum risk here is 15% for a potential 10% on resistance at 45 bucks a share. Not worth it yet, but will pay attention if stock gets over that point.
Vertex (VRTX):
Like the company; recently completed a merger with Aurora Biosciences. I suspect the synergies within the two companies will take some time to emerge, and investor expectations for the two firms are higher than what they should be.. I'm going to wait on this one until they get taken down on sentiment (perhaps to 30 bucks a share?). VRTX is a leader in structural proteomics, and this field should get as hot as fully human monoclonal antibodies did in 2000.. still on the watch list.
Rational (RATL):
Interesting company, one that I like fundamentally, but never liked the stock since it (was) so expensive.
But Rational is crashing down to earth. Worth catching the falling knife without getting the hands too bloodied.
Orders:
* Buy 52 shares INCY @ 19.05/share. If order is filled, place stop loss at 16.45/share.
* Buy 200 shares ASCL @ 4.80/share. If order is filled, place stop loss at 4.08/share.
* Buy 22 shares SNPS @ 46.10/share. If order is filled, place stop loss at 40.50/share.
* Buy 70 shares RATL @ 14.30/share. If order is filled, place stop loss at 11.90/share. |
